With 1.3 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.4 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $42.55 whereas the lowest price it dropped to was $41.51. The 52-week range on QGEN shows that it touched its highest point at $47.92 and its lowest point at $37.63 during that stretch. It currently has a 1-year price target of $49.17. QGEN paid its most recent dividend on 1706572800, while the ex-dividend date for that was 1738108800. Beta for the stock currently stands at 0.64.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QGEN was up-trending over the past week, with a rise of 0.05%, but this was up by 6.76% over a month. Three-month performance dropped to -10.85% while six-month performance fell -0.81%. The stock gained 7.29% in the past year, while it has lost -4.90% so far this year. A look at the trailing 12-month EPS for QGEN yields 0.37 with Next year EPS estimates of 2.48. For the next quarter, that number is 0.50. This implies an EPS growth rate of 1.90% for this year and 8.48% for next year.
Float and Shares Shorts:
At present, 216.12 million QGEN shares are outstanding with a float of 214.41 million shares on hand for trading. On 2025-03-31, short shares totaled 4.04 million, which was 187.0 higher than short shares on 1740700800. In addition to Mr. Thierry Bernard as the firm’s CEO, MD & Member of Management Board, Dr. Roland Sackers serves as its CFO, MD & Member of Management Board.
Institutional Ownership:
Through their ownership of 0.62064 of QGEN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, QGEN reported revenue of $521202000.0 and operating income of $141164000.0. The EBITDA in the recently reported quarter was $204613000.0 and diluted EPS was $0.401143.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for QGEN since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With QGEN analysts setting a high price target of 55.0 and a low target of 43.0, the average target price over the next 12 months is 49.23455. Based on these targets, QGEN could surge 29.9% to reach the target high and rise by 1.56% to reach the target low. Reaching the average price target will result in a growth of 16.28% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.24001 being high and $2.21028 being low. For QGEN, this leads to a yearly average estimate of $2.22019. Based on analyst estimates, the high estimate for the next quarter is $0.57 and the low estimate is $0.54. The average estimate for the next quarter is thus $0.56.
